The Role Of CD30 Overexpression In CD30-positive Non-Hodgkins Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$457,242.00
Summary
The CD30 molecule sits on the surface of normal blood cells, but in a type of cancer called Lymphoma, CD30 concentration is high. The level of expression of CD30 may determine if the cancer cell is killed by the normal defense mechanisms or is able to grow uncontrollably. We are studying the control elements of the CD30 gene to understand how control is lost when the cell becomes cancerous. This knowledge may lead to therapeutic strategies to control lymphoma.
T-cells: The Key To Unlocking Immunity Against Aggressive Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$322,951.00
Summary
By investigating several aspects of patients’ immune defenses against the cancer cells in Diffuse large B-cell lymphoma, this project will provide critical insights on ways to harness the patient’s own immune system to effectively mount anti-tumour responses. These results will pave the way for future therapeutic strategies to successfully treat and prevent lymphoma.
Role Of Ferroptosis In The Lipid Metabolism Of Cancer Cells
Funder
National Health and Medical Research Council
Funding Amount
$238,792.00
Summary
Conventional cancer treatments are becoming increasingly ineffective as cancers mutate to protect cells from drug-activated death. To combat this, new ways to selectively kill cancer cells must be found and therapeutically exploited. This research will study how ferroptosis, a recently discovered form of cell death that is distinct from other killing mechanisms, can be used to target cancer and provide avenues for next-generation cancer treatments.
A Phase I Study Of PiggyBac CD19 Specific Chimeric Antigen Receptor T-cells For Therapy Of Persistent And Relapsed B-cell Leukaemia And Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study).
Funder
National Health and Medical Research Council
Funding Amount
$357,590.00
Summary
Most people with relapsed leukaemia and lymphoma after bone marrow transplant die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but there is little experience in bone marrow transplant patients. We will make leukaemia and lymphoma specific immune cells from normal bone marrow transplant donors, then administer the immune cells to transplant patients to assess their safety and effectiveness.
A Theoretical Framework For Chemotherapy And Immunosuppression
Funder
National Health and Medical Research Council
Funding Amount
$561,028.00
Summary
The team has discovered that potential alternative cell fates behave like autonomous timers, and are in competition in every cell. Variation in selected times within each cell alters the proportion that that die, divide or change into another cell type. The team have produced computational models of cell growth applicable to the immune response and cancer. Here they will apply their discovery to measure the effects of chemotherapeutic drugs and develop new protocols for enhancing the use of such ....The team has discovered that potential alternative cell fates behave like autonomous timers, and are in competition in every cell. Variation in selected times within each cell alters the proportion that that die, divide or change into another cell type. The team have produced computational models of cell growth applicable to the immune response and cancer. Here they will apply their discovery to measure the effects of chemotherapeutic drugs and develop new protocols for enhancing the use of such drugs in the clinic.Read moreRead less
Investigation Of Unique Immune Microenvironment Of Primary CNS Lymphoma
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
This study will investigate how the immune system responds to the development of brain lymphoma. It is expected that this lymphoma develops due to a defective immune response. It is unknown why the tumour is so effective at evading the immune response but if the hypothesis is correct, then the application of new drugs that stimulate the immune system to attack the lymphoma could lead to a marked improvement in survival without the need for toxic chemotherapy and radiation.
A major feature ofcancer is accelerated cell growth and proliferation. One of the major rate-limiting processes that regulates cell growth is the synthesis of ribosomes (the protein synthetic machinery). This study will examine a factor termed UBF whose activity is critical for the regulation of ribosome synthesis. It wll also explore the hypothesis that dysregulation of ribosome biogeneis underlies and contributes to the aetiology of many human cancers.